


ArteraAI Prostate Test


Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)



Personalize Care With Patient-Specific Risk Estimates

For patients diagnosed with mHSPC, medical oncologists face critical treatment intensity and duration decisions that significantly impact both outcomes and quality of life. Other clinical factors, like disease volume, offer prognostic information, but fail to deliver precise individualized disease risk.

The ArteraAI Prostate Test provides a patient-specific 5-year likelihood of prostate cancer-specific mortality (PCSM) based on modern standard of care: doublet hormone therapy (ADT + ARPI)¹. This individualized assessment refines risk stratification beyond volume alone, enabling personalization of therapy intensity and duration.



The ArteraAI Prostate Test utilizes existing biopsy slides with no additional preparation or procedures required.


Science Behind the ArteraAI Prostate Test

ArteraAI Multimodal Artificial Intelligence (MMAI)



The ArteraAI Prostate Test leverages a unique AI algorithm that was developed using data from multiple large, randomized, phase 3 clinical trials. Two types of data, clinical data and biopsy slide image data were used to develop the resulting model and produce an Artera MMAI score.^{1,2} The Artera MMAI score was subsequently validated in the STAMPEDE trial.³

Validation in STAMPEDE

In the doublet hormone therapy arms of the STAMPEDE trial (patients receiving ADT + ARPI), the Artera MMAI score was shown to be significantly prognostic for prostate cancer-specific mortality (PCSM), the key endpoint provided on the ArteraAI Prostate Test Report. The score was also validated as prognostic across other clinical endpoints in the trial.³



Risk Stratification Within Volume Subgroups



The ArteraAI Prostate Test provides the patient's individual MMAI score percentile ranking and 5-year PCSM risk with standard doublet hormone therapy, within metastatic volume subgroups.

*Volume categories per CHAARTED criteria: High Volume: ≥4 bone lesions, with ≥1 outside the spine or pelvis, or presence of visceral metastases; Low Volume: does not meet high volume criteria

ArteraAI Prostate Test Report (mHSPC)

PATIENT DETAILS

PATIENT

Name: **John Doe**
Date of Birth: **08/08/1964**
Condition: **Prostate Cancer**

PHYSICIAN

Name: **Adam Smith, MD**
Clinic Name: **Artera Hospital**

ORDER


Order Date: **MM/DD/YYYY**
Specimen Receipt: **MM/DD/YYYY**
Test Run Date: **MM/DD/YYYY**
Artera ID: **XX-XX-XXX-XXXX**
Accession: **ART-26-XXXXX**

CLINICAL AND PATHOLOGY

Specimen: **Primary Prostate Biopsy**
Clinical Tumor Stage: **T1c**
Pre-Treatment PSA: **3.8 ng/mL**
Patient Age at Order Date: **61**

A

ARTERA MMAI SCORE **0.74**



B

Clinical Interpretation

- In multiple phase III clinical trial cohorts of metastatic prostate cancer, higher MMAI scores were associated with higher rates of prostate cancer-specific mortality in both high and low volume subgroups.^{1,2}
- In patients who received ADT + abiraterone, MMAI score provides more granular risk stratification within metastatic volume subgroups, which may help contextualize outcomes on doublet therapy.
- MMAI score was also prognostic across other key clinical endpoints including time to castration resistant prostate cancer, clinical progression, and overall survival.^{2,3}

*High volume: ≥ 4 bone lesions, with ≥ 1 beyond the spine or pelvis, or visceral metastases.

C

12/04/2024 12:00PM

Reviewed by Laboratory Director
Joshua B. Kish, MD

Review Date and Time (EST)

The ArteraAI Prostate Test results are provided to support risk-based decisions within the recommended guidelines, taking into consideration all other patient factors.

[By signing this I am confirming adequate quality of the material received, image reviewed, and presence of cancer, unless otherwise noted in this report.]

Testing Laboratory: 6800 Southpoint Pkwy, Suite 950, Jacksonville, FL 32216 | CLIA ID: 10D2258449 | Laboratory Director: Joshua B. Kish, MD
© 2026, ARTERA Inc. | TEL: 650 239 7018 | FAX: 650 231 6899 | EMAIL: support@artera.ai

1 of 3

A

Artera MMAI Score: The MMAI score is produced by the ArteraAI test based on the patient's digital pathology image and clinical data.

B


Percentile of MMAI-Defined Risk: There is variability among the patients within the STAMPEDE M1 patient cohorts. The numeric percentile and visualization show how the patient's Artera MMAI score compares to high- and low-volume patients in the STAMPEDE trial (n=1598).


C


Prostate Cancer-Specific Mortality Risk: Estimated 5-year PCSM risk is reported numerically and visually based on patients who received ADT + abiraterone in the STAMPEDE trial (n=542), separated by metastatic disease volume.


Ordering the ArteraAI Prostate Test

Four Easy Steps to Order

- 

1. The ArteraAI Prostate Test is ordered by the treating physician.
- 

2. The original slide used to evaluate the prostate biopsy specimen is sent to our lab for analysis.
- 

3. The test results are sent to the physician.
- 

4. Treating physician and patient review the results together.

If you'd like to learn more about the test or begin ordering, contact sales@artera.ai and someone from Artera will reach out to you.

Cost of Test

The out-of-pocket cost for the ArteraAI Prostate Test will be based on the patient's insurance plan. If the patient is covered by Medicare Plan B, they should have zero out-of-pocket costs for the ArteraAI Prostate Test.

If the patient is covered by private insurance, financial liability will be subject to the terms of the plan taking into consideration copays, coinsurance and deductibles. Artera offers a Financial Assistance Program to eligible patients to ensure out-of-pocket costs are no greater than \$285.

Please contact billing@artera.ai for additional details about the cost of the test, insurance coverage, billing process, and payment options.



References

1. Data on File, Artera, 2026.
2. Esteva A, et al. *NPJ Digit Med.* 2022;5. doi:10.1038/s41746-022-00613-w.
3. Parker C, et al. *Lancet Digital Health.* 2025;7(7):100885. doi:10.1016/j.landig.2025.100885.

The ArteraAI Prostate Test is a Laboratory Developed Test that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Please consult with your health care provider for personalized medical advice and determine if the ArteraAI Prostate Test is appropriate for you.

artera.ai



If you have any questions, please contact Artera® at: info@artera.ai

Artera®. All Rights Reserved.
May 2026, PML 139.A

